Jerry Rosenbaum

Director Center for the Neuroscience of Psychedelics at Massachusetts General Hospital Research Institute

Boston

1

Office Hours

How does this work?
About

Dr. Rosenbaum directed a department of 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as #1 in the United States in 2019 and for 20 of the last 24 years, with 60 specialty clinical and research programs and over 70 million dollars of annual research spending. At MGH, the nation's largest hospital based research institution, with over 1 billion dollars of annual research, he served as Chair of the Executive Committee on Research. 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education, he was 2016 recipient of the Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty for Harvard Medical School. Emeritus Fellow of the ACNP, he is a 2018 Ellis Island Medal of Honor awardee. Past President/Board Chair of the Anxiety and Depression Association of America (ADAA), he served as President and is Board member of the American Foundation for Suicide Prevention. He served a 6 year term as Trustee of the Massachusetts General Hospital and Trustee of the Partners Healthcare System and is co-Chair of Development at MGH. Author of more than 400 original articles and reviews, and 20 books, he led longitudinal studies of children at risk for anxiety disorders and depression, which examined behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders. He currently is building a new MGH center (The Center for Neuroscience of Psychedelics), to use the knowledge of how psychedelics promote neuroplasticity to move the dial on the capacity for change and increase the efficacy of our current treatments, to make the term “treatment resistant” obsolete. He co-founded Psy Therapeutics to advance the discovery of novel drugs for psychiatric and neurologic disorders (www.psythx.com) and is co-founder of Sensorium Therapeutics, Inc.

Ask me about
Psychopharmacology
Work experience

Mar 2020 - Present

Director Centerfor the Neuroscience of Psychedelics

Oct 2019 - Present

Director

The mission of CATSD is to reduce the burden of anxiety and trauma-related disorders in our local, national, and global communities. We use rigorous and open clinical science to investigate the nature and treatment of these disorders. We seek to provide our patients personalized, effective, and compassionate clinical care. Further, we are committed to the successful dissemination of the knowledge and tools produced by these efforts through research, teaching, training, and community partnerships. At all times, we aim for collaboration among these pillars of our program and with stakeholders invested in improving mental health outcomes.

Mar 2016 - Present

Co-Founder

Psy Therapeutics is developing a robust and innovative pipeline of high potential central nervous system (CNS) therapeutics focused on Anxiety Disorders, Major Depressive Disorder and Dementia. We use a flexible approach to increase our R&D productivity by applying validated cutting-edge technologies and strategic collaborations that advance our research programs. www.psythx.com

May 1998 - Present

Stanley Cobb Proessor of Psychiatry

2002 - Oct 2019

Chief of Psychiatry, MGH; Stanley Cobb Professor of Psychiatry, Harvard Medical School

Dr. Rosenbaum directed a department of 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as #1 in the United States in 2019 and for 20 of the last 24 years, with 60 specialty clinical and research programs and over 70 million dollars of annual research spending. At MGH, the nation's largest hospital based research institution, with over 1 billion dollars of annual research, he served as Chair of the Executive Committee on Research. 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education, he was 2016 recipient of the Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty for Harvard Medical School. Emeritus Fellow of the ACNP, he is a 2018 Ellis Island Medal of Honor awardee. Past President/Board Chair of the Anxiety and Depression Association of America (ADAA), he served as President and is a Board member of the American Foundation for Suicide Prevention. He served a 6 year term as Trustee of the Massachusetts General Hospital and Trustee of the Partners Healthcare System and is co-Chair of Development at MGH. Author of more than 400 original articles and reviews, and 20 books, he led longitudinal studies of children at risk for anxiety disorders and depression, which examined behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders. He currently is building a new MGH center, The Center for Neuroscience of Psychedelics, to use the knowledge of how psychedelics promote neuroplasticity to move the dial on the capacity for change and increase the efficacy of our current treatments, to make the term “treatment resistant” obsolete. He co-founded Psy Therapeutics to advance the discovery of novel drugs and diagnostics for psychiatric disorders. www.psythx.com

Jun 1974 - 2000

Massachusetts General Hospital, Harvard Medical School

Resident, Chief of Clinical Psychopharmacology Unit, Associate Chief for Clinical Research,

Education

1969 - 1973

1969 - 1973

Yale Medical School

MD, Medicine,Psychiatry

1965 - 1969

Yale College

BA, American Studies

Talk to Jerry

@ Copyright 2020 OfficeHours Technologies Co.